Loading market dashboard
Novo Nordisk A/S
NVOHealthcareNYSEDK
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Wall Street likes stories, and a big one today is the huge demand for GLP-1 weight-loss drugs. Novo Nordisk got off to an early lead, but Eli Lilly is now the most noted name in the space.
Novo Nordisk (NVO) and Eli Lilly (LLY) are preparing for the next stage of the obesity-drug race, with both companies looking beyond the US for growth as cost r
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novo Nordisk lost momentum in the GLP-1 market. The company's deep pipeline could allow it to bounce back.
Novo Nordisk (NVO) is starting to take its Wegovy pill global, launching the oral weight loss drug in the United Arab Emirates after getting regulatory approval
Live Updates The analyst who called NVIDIA in 2010 just named his top 10 AI stocksThis analyst's 2025 picks are up 106% on average. He just named his top 10 stocks to buy in 2026. Get them here FREE. PANW Stock Falls 30 minutes ago Live Palo Alto Networks (NASDAQ: PANW) is trading lower in premarket... Live Nasdaq Composite: Markets Take a Breather amid Stellar AI Earnings Cycle
Wells Fargo's chief agriculture economist Dr. Michael Swanson told Bloomberg Businessweek on May 29 that GLP-1 weight-loss drugs (Ozempic, Wegovy, Mounjaro, Zepbound) will eventually match statins at roughly 90 million prescriptions, calling the trend “here to stay” because it's prescribed, not faddish.
Novo Nordisk is rated a strong buy, offering a 4.2% yield and trading at a 40% discount to fair value. NVO's growth is temporarily pressured by U.S. price cuts and competition, but volume and product expansion position it for double-digit growth from 2027 onward. The Wegovy franchise, including a high-performing pill, is outpacing competitors internationally, with robust pipeline milestones expected in 2026–2027.
Bitcoin (BTC-USD) underperforms equities amid record ETF outflows and waning institutional demand. MSTR's first Bitcoin sale in nearly four years challenges its 'never sell' narrative, raising questions about treasury strategy.
Novo Nordisk is launching its weight-loss drug Wegovy in the United Arab Emirates, it said in a statement on Wednesday.
Novo Nordisk is launching weight loss pill Wegovy in the United Arab Emirates, the Danish drugmaker said Wednesday. It marks the pill's first launch outside the U.S. market.
The United Arab Emirates becomes the second country to offer the pill after the drugmaker launched it in the U.S. in early January.
Novo Nordisk is launching Wegovy® pill in the UAE, the first country outside the US, to make the Wegovy® pill available to people living with obesity
An upcoming trial result could change how investors think about the weight-loss drug market.
Novo Nordisk's (NYSE:NVO) oral GLP-1 weight-loss drug Wegovy pill continues to outsell Eli Lilly's recently launched competing tablet, but weekly prescription growth is slowing as the market absorbs a new entrant, according to the latest tracking data. GLP-1, or glucagon-like peptide-1, refers to a class of drugs that mimic a gut hormone to suppress appetite and regulate blood sugar, and has become the most hotly contested space in global pharmaceuticals.
Bagsværd, Denmark, 1 June 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.
Novo Nordisk lost its lead in the GLP-1 race, but Eli Lilly's valuation is a bit rich.
Novo Nordisk's (NYSE:NVO) investor relations team presented at Deutsche Bank's European Champions Conference, with the broker maintaining its hold rating and DKK290 target price on the Danish pharma group. The key takeaway concerned the launch of Novo's oral semaglutide product, where the company confirmed that dose escalation patterns are not yet mirroring the trajectory seen with its injectable formulations.
Despite Wall Street skepticism, Novo Nordisk A/S is starting to catch up with Eli Lilly, the market leader in the GLP-1s market. This skepticism mainly reflects declining demand for Ozempic, as well as the weak performance of its long-acting insulin franchise. So, sales of Ozempic fell 12.6% quarter-on-quarter and 15% YoY to about DKK 27.83 billion in Q1.
Not for release to US wire service or distribution in the United States PERTH, Australia, May 28, 2026 (GLOBE NEWSWIRE) -- Novo Resources Corp. (“Novo” or the “Company”) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) is pleased to announce that Tranche 2 of the Placement it announced on 24 and 26 February 2026 (Vancouver)/25 and 26 February 2026 (Perth) (“Placement”) completed today following shareholder approval that was received at the Company's Annual General Meeting (“AGM”) held on 21 May 2026 (Vancouver)/22 May 2026 (Perth). The Company received gross proceeds of ~C$1.93m (approximately A$1.95m) through the issue of the following securities under Tranche 2 of the Placement: ~8.0m Units at C$0.10 per Unit to investors in Canada (with each Unit comprising one common share of Novo (each, a “Common Share”) and one-half (0.5) Common Share purchase warrant (“Unit”)); and ~10.9m Chess Depository Interests (“CDIs”) at A$0.105 per CDI to investors outside of Canada, together with the right to receive one option to purchase one CDI (each an “Option”) for every two CDI's subscribed for under the placement, each Option entitling the holder to purchase one CDI at a price of A$0.15 for a period of three years (with one Common Share underlying each CDI).
There is no reason to panic just yet.
Eli Lilly's fundamentals matter more than Trump's stock purchases.
NVO and AMGN square off as GLP-1 leadership, pipeline depth and diversification shape a compelling healthcare stock comparison.
More than 70% of GLP-1 users in the UBS Evidence Lab survey are eating less fast food.
Novo Nordisk's EU label expansions may widen semaglutide use and boost volumes, but pricing pressure and Lilly rivalry can limit recovery.
Bagsværd, Denmark, 26 May 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.
In the Large-Cap Pharmaceuticals industry, LLY, J&J, NVO and BAYRY are worth retaining as the industry shows some recovery.
Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX) carries a 38.5% implied probability of being acquired before 2027, with all-time volume above $1.68 million on that single contract. The hook is obesity. Viking's VK2735 dual GLP-1/GIP agonist is arguably the most advanced obesity asset not... If Viking Therapeutics Is Acquired, Here's Who Wins
On May 26, 2026, we present a discounted cash flow (DCF) analysis for Novo Nordisk AS (NVO), a company currently facing a challenging price performance with a y
New results from the landmark POSEIDON real-world evidence study at EAS Congress: 2 in 5 people with CVD have CV inflammation - higher risk of heart attack
NVO's Wegovy pill gets CHMP backing, moving it closer to becoming the first oral GLP-1 treatment approved in the EU for weight management.
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Eli Lilly and Novo Nordisk have been vying for dominance in the weight loss drug market. Lilly has gradually surpassed Novo Nordisk, and it now holds 60% of the U.S. market.
Wegovy® 7.2 mg in a single-dose pen has now been recommended by CHMP for approval in the EU Novo Nordisk expects to launch Wegovy® 7.2 mg in a single-dose pen in the EU in Q3 2026 In the STEP UP trial, Wegovy® 7.2 mg demonstrated an average weight loss of 20.7%1, and around one-third of patients achieved 25% or greater weight loss Wegovy® 7.2 mg is already available in the U.S. for adults living with obesity under the brand name Wegovy® HD Bagsværd, Denmark, 22 May 2026 – Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorisation of Wegovy® 7.2 mg (once-weekly injectable semaglutide 7.2 mg) in a single-dose pen for people living with obesity. Wegovy® 7.2 mg is already available in the EU for adults with obesity, dosed as three injections of 2.4 mg, and is based on results from the STEP UP trial programme.
Citi said Eli Lilly and Co's (NYSE:LLY) experimental obesity drug retatrutide has set a new competitive benchmark for the GLP-1 weight-loss market after a...
Citi said Eli Lilly and Co's (NYSE:LLY) experimental obesity drug retatrutide has set a new competitive benchmark for the GLP-1 weight-loss market after a pivotal trial showed patients losing 28% of their body weight over 80 weeks at the highest dose. The results from the TRIUMPH-1 trial, the first dedicated phase III obesity study of the triple agonist drug, were broadly in line with the previously reported TRIUMPH-4 trial in obesity and knee osteoarthritis patients, which showed 28.7% weight loss at 68 weeks.
Novo Nordisk is aiming to slash the time it takes to bring new drugs to market by up to two-thirds using AI, a top executive said, as the Danish drugmaker looks to regain momentum in the booming obesity drugs market.
With a mean weight loss of 16.6%1, Wegovy® pill demonstrates best-in-class weight-loss efficacy and is the first oral GLP-1 treatment recommended by CHMP for weight management in the EU. CHMP recommends Wegovy® pill for approval to reduce excess body weight and maintain long-term weight reduction.
The recommendation paves the way for it to become the first tablet approved to treat obesity in the European Union.
The European Medicines Agency recommended approval for Novo Nordisk's weight-loss pill Wegovy, the regulator said on Friday, clearing its path to become the first oral weight loss drug in Europe, ahead of U.S. rival Eli Lilly.
Eli Lilly's GLP-1 portfolio is driving growth in 2026, with Mounjaro, Zepbound and Foundayo gaining traction across obesity, diabetes and related markets.
Lower prices for weight-loss pills from Novo Nordisk and Eli Lilly are prompting patients to switch from compounded medications to branded Wegovy and Foundayo, according to Reuters interviews with nine U.S. doctors.
Demand for weight-loss drugs has exploded, with material differentiation among the players in the niche. There's a clear leader, but that may not be the best investment option for you in 2026.
Deutsche Bank has maintained its 'hold' rating on Novo Nordisk (NYSE:NVO) with a price target of DKK290 after hosting the Danish drugmaker's head of research and development, Martin Lange. Analyst Emmanuel Papadakis said the key takeaway was that Novo is cautiously optimistic its cagrisema RD11 obesity study will yield a better result than the earlier RD4 trial, which disappointed markets when data was released.
I rated Novo Nordisk a Buy, trading at deep value after a 70% selloff and currently at ~10x trailing earnings. NVO's pipeline, including high-dose Wegovy, zenagamtide, and UBT251, positions it closer to Eli Lilly than market sentiment suggests. Despite pricing and clinical setbacks, the company's stable revenue outlook and potential P/E re-rating support mid-teens annualized returns through 2030.
Novo Nordisk (NOVO) is no longer viewed as a near-term threat, leaving Lilly's (LLY) Tirzepatide to dominate the injectable obesity and Type 2 Diabetes markets for ~1.5-2 years. I expect Foundayo to capture massive global maintenance and "Overweight" markets with >$20B in 2030 sales. Retatrutide is set to monopolize the high-margin Class III Obesity (BMI >40) market, with no direct triple-agonist competition expected until around 2031.
There is a need for more weight loss drug options, including oral pills. Viking Therapeutics is working on a promising one, though tolerability might be an issue.
Eli Lilly (NYSE:LLY | LLY Price Prediction) is the stock everyone wants to talk about, and the reasons are obvious: Mounjaro revenue jumped 125% to $8.66 billion last quarter, the company raised full-year revenue guidance to $82 to $85 billion, and the market cap now sits at roughly $881.8 billion.
Shares of Pfizer, Novo Nordisk, and PDD Holdings trade at incredibly low valuations right now. These stocks are trading at significant discounts relative to their future earnings.
Bagsværd, Denmark,18 May 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.
Novo Nordisk's (NYSE:NVO) oral version of its blockbuster weight-loss drug Wegovy continues to outpace its main competitor despite a slight weekly decline...
Novo Nordisk's (NYSE:NVO) oral version of its blockbuster weight-loss drug Wegovy continues to outpace its main competitor despite a slight weekly decline in prescriptions, according to Citi's latest tracking data. The bank's weekly prescription tracker, based on IQVIA data, showed Wegovy pill reaching approximately 137,000 total prescriptions in its 18th week on the US market, a 4% decline week on week.
Novo Nordisk sees a "major opportunity" outside of the U.S. and says that telehealth partners could help grow the global market for weight loss drugs. The battle for dominance over the lucrative market has so far focused largely on the key U.S. market, currently accounting for more than half of both Novo's and Eli Lilly's respective sales.
Losing muscle, as well as fat, is an unexpected downside of the popular drugs that isn't broadly discussed or immediately apparent.
The bulk of Novo Nordisk's sales come from weight-loss and diabetes treatments. The biotech faces competition from companies like Eli Lilly and Pfizer, among others.
Hims and Hers continues growing rapidly, but shrinking margins and rising costs are beginning to test the company's long-term profitability story.
Novo Nordisk has had a stellar past month at the stock markets with a 25% rise after it touched multi-year lows earlier this year. Fuelling the rise are oral Ozempic and Wegovy pill launches, alongside FDA approvals and telehealth collaborations. The company even managed to trivially raise sales guidance. With low market multiples, I retain a Buy rating as the company's restructuring efforts are beginning to bear fruit.
NVO beats Q1 estimates and raises its 2026 outlook. Meanwhile, Eli Lilly's expanding GLP-1 portfolio threatens its obesity market dominance.
Novo Nordisk recently posted strong quarterly results. Newer launches are boosting sales.
LLY expands beyond tirzepatide with oral obesity pills and next-gen drugs like retatrutide to defend its lead in the booming weight-loss market.
